To further support that the TGF-β signaling pathway was involved in the mechanism of HOXB9-mediated tumorigenesis, HCC cells were treated with TGF-β type I receptor kinase inhibitor, LY364947. This evidence concerns the gene HOXB9 and hepatocellular carcinoma.